Drugs / MELREDABLEUKIN ALFA
MELREDABLEUKIN ALFA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03943550 | May 2019 → Jul 2021 | ulcerative colitis | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT03221179 | Jul 2017 → Jul 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04790916 | Apr → Nov 2021 | autoimmune hepatitis | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MELREDABLEUKIN ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095376 ↗ |
| Known as | RG-7835 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095376 ↗ |
| Known as | RO7049665 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04790916 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5095376 ↗ |
| Route | Subcutaneous | “RO7049665 will be administered SC.” NCT03221179 ↗ |